Request a Call

Request a Call from a
representative

MED INFO LIVE CHAT

Chat with a medical
information specialist

Information for:

UK & IRELAND HEALTHCARE PROFESSIONALS

Click here if you are a healthcare professional and would like more information on Pradaxa® (dabigatran etexilate)


Information intended for:

PATIENTS PRESCRIBED PRADAXA®/ MEMBERS OF THE PUBLIC IN THE UK & IRELAND

Click here for more information on Pradaxa®


PC-GB -101423 V1 August 2020

Cost savings with Pradaxa®
for stroke prevention in NVAF

The cost of prescribing a NOAC needs to be balanced against the financial pressures that failing to prevent stroke brings to families, health services and society.

In the UK the estimated cost to society attributed to stroke is £25.6 billion per year:1,2

£3.6 billion of this is attributed to NHS-funded care (including secondary care, early supported discharge and community rehabilitation)1,2

Approximately £15.8 billion of this is the value of care contributed by informal/unpaid carers1 

The annual cost to society of new cases of stroke is £5.3 billion, of which £1.6 billion is NHS Care. It is estimated that the annual NHS costs of stroke are set to treble from £3.6 billion in 2015 to £10.2 billion in 2035.1,2

Although NICE states that NOACs are cost-effective for stroke prevention in non-valvular atrial fibrillation (NVAF), Clinical Commissioning Groups (CCGs) are under increasing pressure to make savings.3,4 Since the NOAC drug class is one of the top 10 contributors to the total NHS medicine cost, it’s important to consider the potential cost savings that Pradaxa® (dabigatran etexilate) offers versus other NOACs.5,6

Pradaxa® provides cost savings
versus other NOACs

Pradaxa® has the lowest daily cost compared to the other NOACs (rivaroxaban, apixaban and edoxaban), costing only £51.00 per month or £1.70 per day, compared to up to £57.00 per month or £1.90 per day for the other NOACs.6 Compare the Pradaxa® price with those of the other NOACS in the table below.

Cost of NOACs for stroke prevention in NVAF6

NOAC

STRENGTH

Number of days' treatment per pack

NHS List price

Price per day

Pradaxa®

150mg
110mg

30 days (60 capsules)
30 days (60 capsules)

£51.00
£51.00

£1.70

Rivaroxaban

20mg
15mg

28 days (28 capsules)
28 days (28 capsules)

£50.40
£50.40

£1.80

Apixaban

5mg
2.5mg

28 days (56 capsules)
30 days (60 capsules)

£53.20
£57.00

£1.90

Edoxaban

60mg
30mg

28 days (28 capsules)
28 days (28 capsules)

£49.00
£49.00

£1.75

Prices based on NHS list price.6

Savings per patient, per year
versus other NOACs

Pradaxa® offers significant cost savings per patient per year, versus the other NOACs.6

£73.00

per patient
per year
vs apixaban

£36.50

per patient
per year
vs rivaroxaban

£18.25

per patient
per year
vs edoxaban

Prices based on NHS list price.6
Annual savings per patient are calculated by multiplying the difference in the daily price of each drug relative to Pradaxa® by 365. 

Calculate your potential cost savings with Pradaxa® vs other NOACs

Abbreviations

CCG — Clinical Commissioning Group

NICE —  National Institute of Clinical Excellence

NOAC — non-vitamin K antagonist oral anticoagulant

NVAF — non-valvular atrial fibrillation

References
  1. Patel A, et al. Executive summary Part 2: Burden of stroke in the next 20 years and potential returns from increased spending on research. Stroke Association 2017.
  2. Xiang-Ming Xu, et al. The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke. Eur Stroke J 2018;3 (1):82-91.
  3. NICE implementation collaborative consensus: Supporting local implementation of NICE guidance on use of the novel (non-Vitamin K antagonist) oral anticoagulants in non-valvular atrial fibrillation. June 2014. (accessed July 2020).
  4. Robertson R, et al. Understanding NHS financial pressures: How are they affecting patient care? The King’s Fund, London. March 2017. 
  5. Boehringer Ingelheim. Data on File. DBG 18-01.
  6. MIMS.co.uk (accessed July 2020).
PC-GB-100838 V1 | July 2020

Disclaimer

You are about to leave the Boehringer Ingelheim site for a site not created, managed or maintained by Boehringer Ingelheim.

Boehringer Ingelheim hopes that this link will be of interest and use to visitors, but it accepts no liability in relation to the website or its contents and gives no warranty as to the accuracy or completeness of information, data or reports on the website, to the fullest extent that any such liability may be lawfully excluded. Nor does Boehringer Ingelheim necessarily endorse or support any content on the third party website or any further links from their website.